Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis

World Journal of Hepatology

Volumn 6, Issue 6, 2014, Pages 394-409

  Bessone, Fernando ^a   Poles, Natalia ^a   Roma, Marcelo G ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Autoimmune hepatitis; Esteatosis; Hepatitis C; Hepatotoxicity; Lupus hepatitis; Methotrexate; Nonsteroidal anti inflammatory drugs; Regenerative nodular hyperplasia; Systemic lupus erythematosus

Indexed keywords

EID: 84903725869     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i6.394     Document Type: Review

References (138)

1. Schlenker C, Halterman T, Kowdley KV. Rheumatologic disease and the liver. Clin Liver Dis 2011; 15: 153-164 [PMID: 21111998 DOI: 10.1016/j.cld.2010.09.006]
2. Zheng RH, Wang JH, Wang SB, Chen J, Guan WM, Chen MH. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J (Engl) 2013; 126: 260-266 [PMID: 23324274]
3. Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol 2010; 28: 504-510 [PMID: 20609296]
4. Ebert EC, Hagspiel KD. Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011; 45: 436-441 [PMID: 21422947 DOI: 10.1097/MCG.0b013e31820f81b8]
5. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Lanzoni VP, Ferraz ML, Silva AE. Late-onset systemic lupus erythematosus-associated liver disease. Rheumatol Int 2012; 32: 2917-2920 [PMID: 20376663 DOI: 10.1007/s00296-010-1492-4]
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725 [PMID: 9324032 DOI: 10.1002/art.1780400928]
7. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol 2008; 35: 2159-2164 [PMID: 18793002 DOI: 10.3899/jrheum.080336]
8. van Hoek B. The spectrum of liver disease in systemic lupus erythematosus. Neth J Med 1996; 48: 244-253 [PMID: 8710047]
9. Luangjaru S, Kullavanijaya P. Gastrointestinal and hepatobiliary manifestations in systemic lupus erythematosus. J Med Assoc Thai 2005; 88: 71-75
10. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004; 63: 123-129 [PMID: 14722198 DOI: 10.1136/ard.2002.001826]
11. Mackay IR, Taft LI, Cowling DC. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet 1959; 1: 65-69 [PMID: 13621639]
12. Chwalinska-Sadowska H, Milewski B, Nazarewicz T. Clinical and immunomorphological evaluation of pathological changes in the liver in collagenoses. Mater Med Pol 1976; 8: 421-428 [PMID: 1027958 DOI: 10.1016/S0140-6736(59)91136-5]
13. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 1980; 69: 187-194 [PMID: 7405944 DOI: 10.1016/0002-9343(80)90378-2]
14. Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythematosus. J Rheumatol 1981; 8: 752-759 [PMID: 7310775]
15. Miller MH, Urowitz MB, Gladman DD, Blendis LM. The liver in systemic lupus erythematosus. Q J Med 1984; 53: 401-409 [PMID: 6484120]
16. Fox RA, Reichlin MW, Reichilin M, Isenberg DA. Liver function test abnormalities in systemic lupus erythematosus [abstract]. Br J Rheumatol 1997; 36 (Suppl): S10
17. Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, Sato N, Abe H, Aoki Y, Hoshi T, Hashimoto H. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 2000; 20: 366-373 [PMID: 11092254 DOI: 10.1034/j.1600-0676.2000.020005366.x]
18. Takahashi A, Abe K, Saito R, Iwadate H, Okai K, Katsushima F, Monoe K, Kanno Y, Saito H, Kobayashi H, Watanabe H, Ohira H. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med 2013; 52: 1461-1465 [PMID: 23812192 DOI: 10.2169/internalmedicine.52.9458]
19. Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995; 99: 465-472 [PMID: 7485202 DOI: 10.1016/S0002-9343(99)80221-6]
20. Khalifa M, Benjazia E, Rezgui A, Ghannouchi N, Alaoua A, Braham A, Létaief A, Bahri F. [Lupus hepatitis: a case series of 12 patients]. Rev Med Interne 2011; 32: 347-349 [PMID: 21129825 DOI: 10.1016/j.revmed.2010.10.357]
21. Carmona-Fernandes D, Santos MJ, Canhão H, Fonseca JE. Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Med 2013; 11: 98 [PMID: 23557114 DOI: 10.1186/1741-7015-11-98]
22. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317: 265-271 [PMID: 3496538 DOI: 10.1056/NEJM198707303170503]
23. Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 1994; 37: 307-315 [PMID: 8129786 DOI: 10.1002/art.1780370303]
24. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90: 54-62 [PMID: 1986591 DOI: 10.1016/0002-9343(91)90506-S]
25. Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, Shoenfeld Y, Hiepe F, Shun-le C, von Mühlen CA, Locht H, Höpfl P, Wiik A, Reeves W, Fritzler MJ. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006; 13: 77-83 [PMID: 16426003 DOI: 10.1128/CVI.13.1.77-83.2006]
26. Ohira H, Takiguchi J, Rai T, Abe K, Yokokawa J, Sato Y, Takeda I, Kanno T. High frequency of anti-ribosomal P antibody in patients with systemic lupus erythematosus-associated hepatitis. Hepatol Res 2004; 28: 137-139 [PMID: 15036069 DOI: 10.1016/j.hepres.2003.11.008]
27. Koren E, Schnitz W, Reichlin M. Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1325-1328 [PMID: 8216426 DOI: 10.1002/art.1780360917]
28. Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 1992; 89: 1236-1241 [PMID: 1313450 DOI: 10.1172/JCI115707]
29. Nagai T, Arinuma Y, Yanagida T, Yamamoto K, Hirohata S. Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes. Arthritis Rheum 2005; 52: 847-855 [PMID: 15751081 DOI: 10.1002/art.20869]
30. Hulsey M, Goldstein R, Scully L, Surbeck W, Reichlin M. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995; 74: 252-256 [PMID: 7859415 DOI: 10.1006/clin.1995.1037]
31. Calich AL, Bonfa E. The anti-ribosomal P antibodies and prognosis in autoimmune hepatitis. Liver Int 2014; 34: 324 [PMID: 24119250 DOI: 10.1111/liv.12340]
32. de Carvalho JF, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci (Elite Ed) 2009; 1: 501-509 [PMID: 19482664]
33. Beuers U. Hepatic overlap syndromes. J Hepatol 2005; 42 Suppl: S93-S99 [PMID: 15777577 DOI: 10.1016/j.jhep.2004.11.009]
34. Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases. Rheumatology (Oxford) 2007; 46: 1171-1173 [PMID: 17488749 DOI: 10.1093/rheumatology/kem108]
35. Efe C, Purnak T, Ozaslan E, Ozbalkan Z, Karaaslan Y, Altiparmak E, Muratori P, Wahlin S. Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. Scand J Gastroenterol 2011; 46: 732-737 [PMID: 21348808 DOI: 10.3109/00365521.2011.558114]
36. Oka H. The survey of autoimmune hepatitis in Japan. In: Annual Report of the Study Group on Severe Hepatitis. Tokyo: Japanese Ministry of Health and Welfare, 1988: 235-241
37. Tamai Y, Ito K, Kin F, Fukase M. American rheumatism association (ARA) preliminary criteria for the classification of systemic lupus erythematosus and autoimmune hepatitis. Rheumachi 1974; 14: 88-94
38. Leggett BA. The liver in systemic lupus erythematosus. J Gastroenterol Hepatol 1993; 8: 84-88 [PMID: 8439667 DOI: 10.1111/j.1440-1746.1993.tb01179.x]
39. Usta Y, Gurakan F, Akcoren Z, Ozen S. An overlap syndrome involving autoimmune hepatitis and systemic lupus erythematosus in childhood. World J Gastroenterol 2007; 13: 2764-2767 [PMID: 17569152]
40. Efe C, Ozaslan E, Nasiroglu N, Tunca H, Purnak T, Altiparmak E. The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases: report of three cases and review of the literature. Dig Dis Sci 2010; 55: 2417-2421 [PMID: 19826950 DOI: 10.1007/s10620-009-0996-9]
41. Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 1997; 26: 567-572 [PMID: 9303484 DOI: 10.1002/hep.510260306]
42. González LA, Orrego M, Ramírez LA, Vásquez G. Primary biliary cirrhosis/autoimmune hepatitis overlap syndrome developing in a patient with systemic lupus erythematosus: a case report and review of the literature. Lupus 2011; 20: 108-111 [PMID: 20724352 DOI: 10.1177/0961203310378673]
43. Nachbar F, Korting HC, Hoffmann RM, Kollmann M, Meurer M. Unusual coexistence of systemic lupus erythematosus and primary biliary cirrhosis. Dermatology 1994; 188: 313-317 [PMID: 8193407 DOI: 10.1159/000247174]
44. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42: 1194-1202 [PMID: 16250040 DOI: 10.1002/hep.20907]
45. Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, Sella S, Katz BS, Youinou P, Renaudineau Y, Larida B, Invernizzi P, Gershwin ME, Shoenfeld Y. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010; 34: 55-58 [PMID: 19897339 DOI: 10.1016/j.jaut.2009.08.009]
46. Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S, Nakamura Y, Sawasaki T, Endo Y, Nose M. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur J Immunol 2005; 35: 1510-1520 [PMID: 15832294 DOI: 10.1002/eji.200425672]
47. Harada K, Ozaki S, Sudo Y, Tsuneyama K, Ohta H, Nakanuma Y. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol Int 2003; 53: 8-17 [PMID: 12558864 DOI: 10.1046/j.1440-1827.2003.01426.x]
48. Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, Namjou B, Deshmukh H, Bruner G, Espinoza LR, Gilkeson GS, Harley JB, James JA, Nath SK. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One 2008; 3: e0001757 [PMID: 18335026 DOI: 10.1371/journal.pone.0001757]
49. Efe C, Wahlin S, Ozaslan E, Berlot AH, Purnak T, Muratori L, Quarneti C, Yüksel O, Thiéfin G, Muratori P. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol 2012; 24: 531-534 [PMID: 22465972 DOI: 10.1097/MEG.0b013e328350f95b]
50. Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, Menichella R, Ferri S, Cassani F, Bianchi FB, Lenzi M, Muratori L. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009; 104: 1420-1425 [PMID: 19491855 DOI: 10.1038/ajg.2009.126]
51. Efe C, Purnak T, Ozaslan E, Wahlin S. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2010; 105: 226; author reply 226-227 [PMID: 20054319 DOI: 10.1038/ajg.2009.602]
52. Oh DC, Ng TM, Ho J, Leong KP. Systemic lupus erythematosus with concurrent protein-losing enteropathy and primary sclerosing cholangitis: a unique association. Lupus 2006; 15: 102-104 [PMID: 16539281 DOI: 10.1191/0961203306lu2251cr]
53. Kadokawa Y, Omagari K, Matsuo I, Otsu Y, Yamamoto U, Nishino T, Ohba K, Miyazaki M, Harada T, Taguchi T, Kohno S. Primary sclerosing cholangitis associated with lupus nephritis: a rare association. Dig Dis Sci 2003; 48: 911-914 [PMID: 12772788 DOI: 10.1023/A:1023095428321]
54. Audan A, Bruley Des Varannes S, Georgelin T, Sagan C, Cloarec D, Serraz H, Le Bodic L. [Primary sclerosing cholangitis and systemic lupus erythematosus]. Gastroenterol Clin Biol 1995; 19: 123-126 [PMID: 7720973]
55. Lamy P, Valla D, Bourgeois P, Rueff B, Benhamou JP. [Primary sclerosing cholangitis and systemic lupus erythematosus]. Gastroenterol Clin Biol 1988; 12: 962-964 [PMID: 3069553]
56. Bargellesi A, Vigi V, Conconi F. [Further research on the intracellular "pool" of alpha-globin in beta-thalassemia]. Boll Soc Ital Biol Sper 1968; 44: 1666-1668 [PMID: 5720242 DOI: 10.2174/1568010053622821]
57. Ramos-Casals M, Font J, García-Carrasco M, Cervera R, Jiménez S, Trejo O, de la Red G, Sánchez-Tapias JM, Ingelmo M. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43: 2801-2806 [PMID: 11145039 DOI: 10.1002/1529-0131(200012)43:12<2801::AID-ANR21>3.0.CO;2-V]
58. Ahmed MM, Berney SM, Wolf RE, Hearth-Holmes M, Hayat S, Mubashir E, Vanderheyde H, Chang WL, King JW. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 2006; 331: 252-256 [PMID: 16702794 DOI: 10.1097/00000441-200605000-00003]
59. Perlemuter G, Cacoub P, Sbaï A, Hausfater P, Thibault V, Le TH, Wechsler B, Buffet C, Piette JC. Hepatitis C virus infection in systemic lupus erythematosus: a case-control study. J Rheumatol 2003; 30: 1473-1478 [PMID: 12858443 DOI: 10.1016/S0168-8278(00)81019-3]
60. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997; 26: 689-701 [PMID: 9062950 DOI: 10.1016/S0049-0172(97)80005-4]
61. Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatology. J Viral Hepat 1997; 4 Suppl 2: 42-47 [PMID: 9429209]
62. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263 [PMID: 10398604]
63. Sansonno D, Cornacchiulo V, Iacobelli AR, Gatti P, Distasi M, Dammacco F. Hepatitis C virus infection and clonal B-cell expansion. Clin Exp Rheumatol 1996; 14 Suppl 14: S45-S50 [PMID: 8722199]
64. Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K. Systemic lupus erythematosus after alphainterferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol 2000; 95: 310-312 [PMID: 10638610 DOI: 10.1111/j.1572-0241.2000.01715.x]
65. Danesh FR, Lynch P, Kanwar YS. Lupus membranous glomerulonephritis mimicking hepatitis C-associated nephropathy. Am J Kidney Dis 2002; 39: E19 [PMID: 11877599 DOI: 10.1053/ajkd.2002.31430]
66. Albero MD, Rivera F, Merino E, Gil MT, Jimenez LA, Aranda I, Olivares J. Hepatitis C virus infection complicating lupus nephritis. Nephrol Dial Transplant 1996; 11: 1342-1345 [PMID: 8672035 DOI: 10.1093/ndt/11.7.1342]
67. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, Zuckerman E. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134-139 [PMID: 17029886 DOI: 10.1016/j.jaut.2006.07.005]
68. Vaiphei K, Bhatia A, Sinha SK. Liver pathology in collagen vascular disorders highlighting the vascular changes within portal tracts. Indian J Pathol Microbiol 2011; 54: 25-31 [PMID: 21393872 DOI: 10.4103/0377-4929.77319]
69. Takahaski C, Kumagai S, Tsubata R, Sorachi K, Ozaki S, Imura H, Nakao K. Portal hypertension associated with anticardiolipin antibodies in a case of systemic lupus erythematosus. Lupus 1995; 4: 232-235 [PMID: 7655497]
70. Hubscher O, Elsner B. Nodular transformation of the liver in a patient with systemic lupus erythematosus. J Rheumatol 1989; 16: 410-412 [PMID: 2724260]
71. Morlá RM, Ramos-Casals M, García-Carrasco M, Cervera R, Font J, Bruguera M, Rojas-Rodríguez J, Ingelmo M. Nodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature. Lupus 1999; 8: 160-163 [PMID: 10192512 DOI: 10.1191/096120399678847515]
72. Plessier A, Rautou PE, Valla DC. Management of hepatic vascular diseases. J Hepatol 2012; 56 Suppl 1: S25-S38 [PMID: 22300463 DOI: 10.1016/S0168-8278(12)60004-X]
73. Foster JM, Litwin A, Gibbs JF, Intengen M, Kuvshinoff BW. Diagnosing regenerative nodular hyperplasia, the "great masquerader" of liver tumors. J Gastrointest Surg 2006; 10: 727-733 [PMID: 16713546 DOI: 10.1016/j.gassur.2005.10.010]
74. Zech CJ, Seiderer J, Reinisch W, Ochsenkuhn T, Schima W, Diebold J, Wrba F, Reiser MF, Schoenberg SO. Thioguanininduced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur Radiol 2007; 17: 1898-1905 [PMID: 17221208 DOI: 10.1007/s00330-006-0544-3]
75. Laharie D, Vergniol J, Bioulac-Sage P, Diris B, Poli J, Foucher J, Couzigou P, Drouillard J, de Lédinghen V. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010; 22: 487-493 [PMID: 19940782 DOI: 10.1097/MEG.0b013e328334098f]
76. Ames JT, Federle MP, Chopra K. Distinguishing clinical and imaging features of nodular regenerative hyperplasia and large regenerative nodules of the liver. Clin Radiol 2009; 64: 1190-1195 [PMID: 19913129 DOI: 10.1016/j.crad.2009.07.015]
77. Haslock I. Spontaneous rupture of the liver in systemic lupus erythematosus. Ann Rheum Dis 1974; 33: 482-484 [PMID: 4424438 DOI: 10.1136/ard.33.5.482]
78. Bralet MP, Terris B, Vilgrain V, Brégeaud L, Molas G, Corbic M, Belghiti J, Fléjou JF, Degott C. Epithelioid hemangioendothelioma, multiple focal nodular hyperplasias, and cavernous hemangiomas of the liver. Arch Pathol Lab Med 1999; 123: 846-849 [PMID: 10458838]
79. Berzigotti A, Frigato M, Manfredini E, Pierpaoli L, Mulè R, Tiani C, Zappoli P, Magalotti D, Malavolta N, Zoli M. Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus. World J Gastroenterol 2011; 17: 4503-4508 [PMID: 22110281 DOI: 10.3748/wjg.v17.i40.4503]
80. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985; 5: 1194-1200 [PMID: 4065824 DOI: 10.1002/hep.1840050622]
81. Folomeev M, Dougados M, Beaune J, Kouyoumdjian JC, Nahoul K, Amor B, Alekberova Z. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992; 1: 191-195 [PMID: 1301981 DOI: 10.1177/096120339200100312]
82. Robak E, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw 2001; 12: 445-452 [PMID: 11566625]
83. Robak E, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002; 11: 348-355 [PMID: 12139372 DOI: 10.1191/0961203302lu199oa]
84. van Tuyll van Serooskerken AM, Habets JM, Badeloe S, Poblete-Gutiérrez P, Frank J. Porphyria cutanea tarda in pre-existent lupus erythematosus--is there an association? Int J Dermatol 2007; 46 Suppl 3: 50-52 [PMID: 17973893 DOI: 10.1111/j.1365-4632.2007.03515.x]
85. Gibson GE, McEvoy MT. Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients. J Am Acad Dermatol 1998; 38: 569-573 [PMID: 9555796 DOI: 10.1016/S0190-9622(98)70119-7]
86. Fritsch S, Wojcik AS, Schade L, Machota Junior MM, Brenner FM, Paiva Edos S. Increased photosensitivity? Case report of porphyria cutanea tarda associated with systemic lupus erythematosus. Rev Bras Reumatol 2012; 52: 968-970 [PMID: 23223706]
87. Haendchen L, Jordão JM, Haider O, Araújo F, Skare TL. Porphyria cutanea tarda and systemic lupus erythematosus. An Bras Dermatol 2011; 86: 173-175
88. Cram DL, Epstein JH, Tuffanelli DL. Lupus erythematosus and porphyria. Coexistence in seven patients. Arch Dermatol 1973; 108: 779-784 [PMID: 4587578 DOI: 10.1001/archderm.1973.01620270005001]
89. Bissell DM, Schmid R. Hepatic porphyrias. In: Schiff L, Schiff ER. Disease of the Liver - 6th Ed. Philadelphia, Toronto: JB Lippincott, 1987: 1075-1092
90. Huang D, Aghdassi E, Su J, Mosko J, Hirschfield GM, Gladman DD, Urowitz MB, Fortin PR. Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. J Rheumatol 2012; 39: 254-261 [PMID: 22174205 DOI: 10.3899/jrheum.110310]
91. Lozovoy MA, Simão AN, Panis C, Rotter MA, Reiche EM, Morimoto HK, Lavado E, Cecchini R, Dichi I. Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus. Lupus 2011; 20: 1250-1259 [PMID: 21813592 DOI: 10.1177/0961203311411350]
92. McKinnon RA, Nebert DW. Possible role of cytochromes P450 in lupus erythematosus and related disorders. Lupus 1994; 3: 473-478 [PMID: 7704004 DOI: 10.1177/096120339400300608]
93. Kovacic P, Jacintho JD. Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: unifying theme of oxidative stress. Mini Rev Med Chem 2003; 3: 568-575 [PMID: 12871159 DOI: 10.2174/1389557033487926]
94. Horizon AA, Wallace DJ. Risk: benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf 2004; 3: 273-278 [PMID: 15268645 DOI: 10.1517/14740338.3.4.273]
95. Bessone F, Colombato L, Fassio E, Reggiardo MV, Vorobioff J, Tanno H. The spectrum of nimesulide-induced-hepatotoxicity. An overview. Anti-Inflamm Anti-Allergy Agents Med Chem 2010; 9: 355-365 [DOI: 10.2174/1871523011009040355]
96. Bessone F, Colombato L, Pasamonti ME, Godoy A, Vorobioff J, Tanno H. Nimesulide: clinical and histological evidences of severe hepatotoxicity. J Hepatol 2001; 34 (Suppl 1): 46
97. Bessone F, Tanno H. [Hepatotoxicity induced by non-steroidal anti-inflammatory drugs]. Gastroenterol Hepatol 2000; 23: 200-205 [PMID: 10863862]
98. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenacassociated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-827 [PMID: 7657288 DOI: 10.1016/0270-9139(95)90303-8]
99. Seaman WE, Ishak KG, Plotz PH. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 1974; 80: 1-8 [PMID: 4810348 DOI: 10.7326/0003-4819-80-1-1]
100. Travers RL, Hughes GR. Salicylate hepatotoxicity in systemic lupus erythematosus: a common occurrence? Br Med J 1978; 2: 1532-1533 [PMID: 728711 DOI: 10.1136/bmj.2.6151.1532-a]
101. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981; 141: 333-342 [PMID: 7469624 DOI: 10.1001/archinte.1981.00340030065013]
102. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-5661 [PMID: 21128314 DOI: 10.3748/wjg.v16.i45.5651]
103. Russell AS, Sturge RA, Smith MA. Serum transaminases during salicylate therapy. Br Med J 1971; 2: 428-429 [PMID: 5576002 DOI: 10.1136/bmj.2.5759.428]
104. Rainsford KD. Side-effects and toxicology of the salicylates. In: Rainsford KD. Aspirin and Related Drugs. Boca Raton, Florida: CRC Press, 2004: 367-554
105. Teoh NC, Farrell GC. Hepatotoxicity associated with nonsteroidal anti-inflammatory drugs. Clin Liver Dis 2003; 7: 401-413 [PMID: 12879991]
106. De Santis M, Crotti C, Selmi C. Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol 2013; 27: 543-551 [PMID: 24090941 DOI: 10.1016/j.bpg.2013.06.016]
107. Cohen-Ezra O, Avni Y, Morgenstern S, Ben-Ari Z. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease]. Harefuah 2012; 151: 675-68, 721 [PMID: 23330258]
108. Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 2013; 38: 1025-1037 [PMID: 24099468 DOI: 10.1111/apt.12490]
109. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997; 23: 883-915 [PMID: 9361160 DOI: 10.1016/S0889-857X(05)70365-3]
110. Phillips CA, Cera PJ, Mangan TF, Newman ED. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992; 19: 229-233 [PMID: 1629819]
111. Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995; 38: 1115-1119 [PMID: 7639808 DOI: 10.1002/art.1780380814]
112. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-1104 [PMID: 19060002 DOI: 10.1136/ard.2008.093690]
113. Beyeler C, Reichen J, Thomann SR, Lauterburg BH, Gerber NJ. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997; 36: 338-344 [PMID: 9133966 DOI: 10.1093/rheumatology/36.3.338]
114. Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 2001; 7: 224-227 [PMID: 17039139 DOI: 10.1097/00124743-200108000-00007]
115. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Murphy G, Østergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-1093 [PMID: 19033291 DOI: 10.1136/ard.2008.094474]
116. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485 [PMID: 19493586 DOI: 10.1016/j.jaad.2009.03.027]
117. Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén E, Gisbert JP, Moreno-Otero R. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011; 137: 637-639 [PMID: 21719043 DOI: 10.1016/j.medcli.2010.12.024]
118. Barbero-Villares A, Mendoza Jiménez-Ridruejo J, Taxonera C, López-Sanromán A, Pajares R, Bermejo F, Pérez-Calle JL, Mendoza JL, Algaba A, Moreno-Otero R, Maté J, Gisbert JP. Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47: 575-579 [PMID: 22229701 DOI: 10.3109/00365521.2011.647412]
119. Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MG, van de Kerkhof PC, Drenth JP. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27: 639-645 [PMID: 17498249 DOI: 10.1111/j.1478-3231.2007.01489.x]
120. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009; 36: 539-545 [PMID: 19208607 DOI: 10.3899/jrheum.080576]
121. Dávila-Fajardo CL, Swen JJ, Cabeza Barrera J, Guchelaar HJ. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics 2013; 14: 63-73 [PMID: 23252949 DOI: 10.2217/pgs.12.183]
122. Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. J Pharmacol Pharmacother 2012; 3: 248-253 [PMID: 23129960]
123. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1612-1617 [PMID: 20448284 DOI: 10.1136/ard.2009.112136]
124. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M. Liver injury from tumor necrosis factor-a antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 558-564.e3 [PMID: 23333219 DOI: 10.1016/S0168-8278(12)61353-1]
125. Leak AM, Rincon-Aznar B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 2008; 35: 2286-2287 [PMID: 19004062 DOI: 10.3899/jrheum.080521]
126. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001; 76: 84-86 [PMID: 11155419 DOI: 10.4065/76.1.84]
127. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-581 [PMID: 16547695 DOI: 10.1007/s10067-005-0169-y]
128. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48: 716-720 [PMID: 19416947 DOI: 10.1093/rheumatology/kep080]
129. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-251 [PMID: 17632266 DOI: 10.1097/MD.0b013e3181441a68]
130. Seto W-K, Chan TSY, Hwang Y-Y, Choi O, Wong D, Fung J, Lie A K-W, Lai C-L, Kwong Y-L, Yuen M-F. Interim analysis of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplant: a prospective study. Hepatology 2013; 58 (Suppl): 650A [DOI: 10.1002/hep.26727]
131. Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009; 48: 448-450 [PMID: 19223285 DOI: 10.1093/rheumatology/kep003]
132. Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: casebased review. Clin Rheumatol 2013; 32: 1099-1106 [PMID: 23604593 DOI: 10.1007/s10067-013-2245-z]
133. Soubrier M, Mathieu S, Hermet M, Makarawiez C, Bruckert E. Do all lupus patients need statins? Joint Bone Spine 2013; 80: 244-249 [PMID: 23098926 DOI: 10.1016/j.jbspin.2012.08.014]
134. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-161 [PMID: 11315345 DOI: 10.1191/096120301671376017]
135. Bacon AM, Rosenberg SA. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982; 97: 62-63 [PMID: 7092009]
136. Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78: 222-223 [PMID: 3975725 DOI: 10.1097/00007611-198502000-00034]
137. Subramaniam SR, Cader RA, Mohd R, Yen KW, Ghafor HA. Low-dose cyclophosphamide-induced acute hepatotoxicity. Am J Case Rep 2013; 14: 345-349 [PMID: 24023976 DOI: 10.12659/AJCR.889401]
138. Her M, Lee Y, Jung E, Kim T, Kim D. Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int 2011; 31: 79-84 [PMID: 19885660 DOI: 10.1007/s00296-009-1237-4]